News | Mammography | June 15, 2016

Hologic Leads All Vendors in Latest KLAS Tomosynthesis Report

Mammography customers highlight Hologic's high image quality, strong customer support and product innovations, including Genius 3-D Mammography

Hologic, KLAS Research, Tomosynthesis 2016, Genius 3-D Mammography, Selenia Dimensions

June 15, 2016 — Hologic announced that the company received top marks from U.S. mammography providers in a new independent report from KLAS Research, with 96 percent of customers reporting that Hologic systems are worth the investment.

In the KLAS report, Tomosynthesis 2016, doctors, directors of radiology and C-suite executives scored Hologic highest in overall product satisfaction and confidence that the company will continue to lead the development of the tomosynthesis market. The in-depth survey, which was not commissioned by Hologic, surveyed decision makers at 48 organizations with breast tomosynthesis systems installed.

"Hologic seems to be the only company that really understands the tomosynthesis market," a director of radiology told KLAS. "It was clear from our implementation and our usage of their system that they are a full generation ahead of other vendors. Everybody else is playing catch-up." Hologic has scored highest in the mammography market in all five KLAS Tomosynthesis reports.

Provider respondents noted Hologic's high image quality, strong customer service and implementation guidance as key reasons for new system purchases. Additionally, more than 91 percent of respondents reported a sense of confidence that Hologic's pace of development will continue to allow for leadership in tomosynthesis product innovation — a significantly higher score than that of other manufacturers.

The Genius 3-D Mammography exam is U.S. Food and Drug Administration (FDA)-approved and only available on the Hologic Selenia Dimensions system. According to Hologic, the Genius exam is the only mammogram proven to reduce unnecessary callbacks by up to 40 percent, and detect 41 percent more invasive cancers than conventional mammography alone.

For more information: www.hologic.com

Related Content

Radiologists have recently taken on the role of activists and are tackling pressing issues in healthcare, including breast density

Getty Images

Feature | Women's Health | January 20, 2021 | By Fazila Seker, Ph.D.
Radiologists — who have long been professionals in the metaphorical and literal back-rooms of healthcare — have recen
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...